clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT01615978 |
P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
P17 | country | Japan | Q17 |
P582 | end time | 2004-03-01 | |
P4135 | maximum age | 64 | |
P1050 | medical condition | diabetes | Q12206 |
P2899 | minimum age | 20 | |
P1132 | number of participants | 15 | |
P4844 | research intervention | liraglutide | Q2526479 |
P6153 | research site | Novo Nordisk | Q818846 |
P580 | start time | 2003-12-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Randomised, Double-blind Within Dose Group, Single-centre, Placebo-controlled, Parallel 2-different Dose Group, 14-day Multiple s.c. Doses Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Subjects With Type 2 Diabetes |
Search more.